Identification of Highly-Protective combinations of plasmodium vivax recombinant proteins for vaccine development
Loading...
Download
Associated Records
Authors
File Licence
Editors
Date
2017-09-26
Source Title
eLife
Journal Title
Journal ISSN
Volume Title
Publisher
eLIFE SCIENCES PUBL LTD
Melbourne Authors
Affiliation
Medical Biology (W.E.H.I.)
Document Type
Journal Article
Subject Code
Citation
França, C. T., White, M. T., He, W. Q., Hostetler, J. B., Brewster, J., Frato, G., Malhotra, I., Gruszczyk, J., Huon, C., Lin, E., Kiniboro, B., Yadava, A., Siba, P., Galinski, M. R., Healer, J., Chitnis, C., Cowman, A. F., Takashima, E., Tsuboi, T. ,... Mueller, I. (2017). Identification of Highly-Protective combinations of plasmodium vivax recombinant proteins for vaccine development. Elife, 6, https://doi.org/10.7554/eLife.28673.
Access Status
Open Access
Access URL
Open Access URL
Open Access at PMC
Linked Resource URL
NHMRC Grant Code
ARC Grant Code
Description
Abstract
The study of antigenic targets of naturally-acquired immunity is essential to identify and prioritize antigens for further functional characterization. We measured total IgG antibodies to 38 P. vivax antigens, investigating their relationship with prospective risk of malaria in a cohort of 1-3 years old Papua New Guinean children. Using simulated annealing algorithms, the potential protective efficacy of antibodies to multiple antigen-combinations, and the antibody thresholds associated with protection were investigated for the first time. High antibody levels to multiple known and newly identified proteins were strongly associated with protection (IRR 0.44-0.74, p<0.001-0.041). Among five-antigen combinations with the strongest protective effect (>90%), EBP, DBPII, RBP1a, CyRPA, and PVX_081550 were most frequently identified; several of them requiring very low antibody levels to show a protective association. These data identify individual antigens that should be prioritized for further functional testing and establish a clear path to testing a multicomponent P. vivax vaccine.